Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis

Overview

Journal Lung

Specialty Pulmonary Medicine

Date 2024 Jun 19

PMID 38898129

Authors

Xiaoying Chen

Haopeng Zhi

Xiaohu Wang

Zicong Zhou

Huiting Luo

Jing Li

Roma Sehmi

Paul M OByrne

Ruchong Chen

Affiliations

Soon will be listed here.

Abstract

Background: Treatment of allergic bronchopulmonary aspergillosis (ABPA) is challenging. Biological therapies have been reported as adjunctive treatments for ABPA, primarily in case series or case reports. This study aimed to analyze the efficacy of biologics for managing ABPA both qualitatively and quantitatively.

Methods: All articles on APBA published in October 2023 were searched in PubMed, Web of Science, ClinicalTrials.gov, and Embase databases. The effects of interest were the mean changes from baseline for outcomes, including exacerbation rates, oral corticosteroids usage (OCS), and total immunoglobulin E (IgE) levels. Reported outcomes were quantitatively synthesized by usual or individual patient data (IPD) meta-analyses. PROSPERO registration number: CRD42022373396.

Results: A total of 86 studies were included in the systematic review including 346 patients. Sixteen studies on omalizumab were pooled for the usual meta-analysis. Omalizumab therapy significantly reduced exacerbation rates (- 2.29 [95%CI - 3.32, - 1.26]), OCS dosage (- 10.91 mg [95%CI - 18.98, - 2.85]), and total IgE levels (- 273.07 IU/mL [95%CI - 379.30, - 166.84]), meanwhile improving FEV1% predicted (10.09% [95%CI 6.62, 13.55]). Thirty-one studies on dupilumab, mepolizumab, or benralizumab were pooled to perform an IPD meta-analysis, retrospectively. Both dupilumab and mepolizumab significantly reduced exacerbation rates, OCS, and total IgE levels. Benralizumab showed a similar trend, but it was not statistically significant. Tezepelumab showed weak evidence of its effects on ABPA. All five biologics led to milder clinical symptoms (e.g., cough, wheezing) with serious adverse effects that happened once in omalizumab treatment.

Conclusion: These results indicate the clinical benefit of omalizumab, dupilumab, and mepolizumab in patients with ABPA. Further randomized, controlled studies with a larger sample size and longer follow-up are needed to confirm these findings.

Citing Articles

LUNG Year in Review: 2024.

Dicpinigaitis P Lung. 2025; 203(1):29.

PMID: 39841240 DOI: 10.1007/s00408-025-00785-8.

References

Denning D, Pleuvry A, Cole D . Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2012; 51(4):361-70. DOI: 10.3109/13693786.2012.738312. View

Riscili B, Wood K . Noninvasive pulmonary Aspergillus infections. Clin Chest Med. 2009; 30(2):315-35, vii. DOI: 10.1016/j.ccm.2009.02.008. View

Agarwal R, Sehgal I, Dhooria S, Muthu V, Prasad K, Bal A . Allergic bronchopulmonary aspergillosis. Indian J Med Res. 2020; 151(6):529-549. PMC: 7602921. DOI: 10.4103/ijmr.IJMR_1187_19. View

Keown K, Abbott S, Kuzeljevic B, Rayment J, Chilvers M, Yang C . An investigation into biomarkers for the diagnosis of ABPA and aspergillus disease in cystic fibrosis. Pediatr Pulmonol. 2019; 54(11):1787-1793. DOI: 10.1002/ppul.24465. View

Kumar R . Mild, moderate, and severe forms of allergic bronchopulmonary aspergillosis: a clinical and serologic evaluation. Chest. 2003; 124(3):890-2. DOI: 10.1378/chest.124.3.890. View

Muthu V, Sehgal I, Prasad K, Dhooria S, Garg M, Aggarwal A . Epidemiology and outcomes of allergic bronchopulmonary aspergillosis in the elderly. Mycoses. 2021; 65(1):71-78. DOI: 10.1111/myc.13388. View

Agarwal R, Bansal S, Chakrabarti A . Are allergic fungal rhinosinusitis and allergic bronchopulmonary aspergillosis lifelong conditions?. Med Mycol. 2016; 55(1):87-95. DOI: 10.1093/mmy/myw071. View

Agarwal R, Gupta D, Aggarwal A, Behera D, Jindal S . Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest. 2006; 130(2):442-8. DOI: 10.1378/chest.130.2.442. View

Patterson R, Greenberger P, Halwig J, Liotta J, Roberts M . Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med. 1986; 146(5):916-8. DOI: 10.1001/archinte.146.5.916. View

10.

TUCKER R, Haq Y, Denning D, Stevens D . Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother. 1990; 26(4):561-6. DOI: 10.1093/jac/26.4.561. View

11.

Benitez L, Carver P . Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents. Drugs. 2019; 79(8):833-853. DOI: 10.1007/s40265-019-01127-8. View

12.

Tverdek F, Kofteridis D, Kontoyiannis D . Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther. 2016; 14(8):765-76. DOI: 10.1080/14787210.2016.1199272. View

13.

Zhou Z, Yin X, Zhang Y, Shao Q, Mao X, Hu W . Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database. Front Pharmacol. 2022; 13:891336. PMC: 9098189. DOI: 10.3389/fphar.2022.891336. View

14.

Gresnigt M, Netea M, van de Veerdonk F . Pattern recognition receptors and their role in invasive aspergillosis. Ann N Y Acad Sci. 2012; 1273:60-7. DOI: 10.1111/j.1749-6632.2012.06759.x. View

15.

Humbert M, Bousquet J, Bachert C, Palomares O, Pfister P, Kottakis I . IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. J Allergy Clin Immunol Pract. 2019; 7(5):1418-1429. DOI: 10.1016/j.jaip.2019.02.030. View

16.

Schuyler M . The Th1/Th2 paradigm in allergic bronchopulmonary aspergillosis. J Lab Clin Med. 1998; 131(3):194-6. DOI: 10.1016/s0022-2143(98)90089-0. View

17.

Lewington-Gower E, Chan L, Shah A . Review of current and future therapeutics in ABPA. Ther Adv Chronic Dis. 2021; 12:20406223211047003. PMC: 8543630. DOI: 10.1177/20406223211047003. View

18.

Eraso I, Sangiovanni S, Morales E, Fernandez-Trujillo L . Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review. Ther Adv Respir Dis. 2020; 14:1753466620961648. PMC: 7576923. DOI: 10.1177/1753466620961648. View

19.

Epps Q, Epps K, Zobell J, Young D . Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations:  II. Therapies for allergic bronchopulmonary aspergillosis. Pediatr Pulmonol. 2020; 55(12):3541-3572. DOI: 10.1002/ppul.25080. View

20.

Li J, Fan L, Li M, Cao W, Xu J . Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature. Respir Med. 2016; 122:33-42. DOI: 10.1016/j.rmed.2016.11.019. View